For Clinicians | MenACWY vs MenB

For Clinicians | MenACWY vs MenB

A Back-to-School Meningococcal Vaccine Refresher

By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, Jase
Medically reviewed and edited by Kristen Carpenter, PA-C

Fall is coming, and with that are newly minted college students heading off to live in the dorms. That means meningitis is particularly top of mind. While the disease itself isn’t seasonal, the vaccines feel like they are because this is the moment when parents and students consider them more than ever as many college forms require action with the vaccine. To add to the confusion, there are two separate vaccines, plus combination products. MenACWY is routine and MenB isn’t, exactly. And the two pentavalent products that cover both can’t be swapped for each other partway through a series.

Parents ask whether the shot their kid got at 11 still counts, and a fair number of us have to look it up before we answer. I know I do! The meningococcal schedule has been revised more than once since most of us trained, and the version we memorized had fewer moving parts.

So this is a refresher on meningitis vaccines for you: what’s routine, which products follow which, and what these vaccines don’t cover.

Which one does the college form actually require?

MenACWY, almost always.

CDC recommends MenACWY routinely for every adolescent, first dose at 11 to 12 and a booster at 16.¹ That’s what most state college-entry requirements are built around, and most of those apply to students living in on-campus housing rather than to everyone enrolled. The rules vary by state and they get revised, so check the state your student is moving to, not the one they’re leaving.

So when a family tells you “she already got the meningitis shot,” they almost always mean MenACWY, and they’re usually right that the form is handled. 

MenB is an option, not a default

So a parent will inevitably ask you in the next few weeks: “Does she need MenB too? What even is that?”

MenACWY covers four of the five serogroups that cause most disease. MenB covers the fifth. For a healthy teenager, MenB isn’t automatic. This bug gets killed by one particular part of the immune system, so when that part is missing, broken, or switched off by a medication, catching it is a much bigger deal. That’s kids without a working spleen, kids born with a gap in that defense, and anyone on eculizumab or a drug like it, which raises the risk roughly 2,000-fold.² Lab workers who handle the bacteria and anyone caught in a B outbreak, too.² All of them get MenB.

So why isn’t it routine for everyone else? Incidence is very low, and MenB gives what ACIP itself calls short-term protection.² Rare disease plus short-lived protection is a hard case for universal vaccination. Against that, serogroup B caused every US college outbreak from 2011 to 2019.³ Both of those are true at once, which is how this became a conversation instead of a rule. You and the family decide together if this vaccine is right, and ACIP calls that shared clinical decision-making.

Vaccine Schedules

This is the part that trips people up, and it’s the easiest one to miss on a records review.

There are two combination shots that cover all five serogroups in one injection: Penbraya from Pfizer and Penmenvy from GSK. 

• The MenB half has to match all the way through. Penbraya carries Pfizer’s MenB antigen, so the second MenB dose is Trumenba. Penmenvy carries GSK’s, so the second dose is Bexsero.⁴
• The two combination shots aren’t interchangeable with each other. Don’t start with one and finish with the other.⁴
• A combination shot is for the visit where the student is due for MenACWY and has already decided on MenB. It doesn’t replace the routine MenACWY schedule on its own.⁴
• MenB is two doses, 0 and 6 months, for healthy 16 to 23 year olds.² Start at 16 and the series is finished well before move-in.

So when a student turns up with a partial series, the question is which brand, not just which vaccine. If the record says “MenB” and nothing else, get the product name before you give dose two.

Why neither the shot record nor the rash rules bacterial meningitis out

Meningitis isn’t one disease. It’s inflammation of the meninges, and the causes run from enteroviruses to pneumococcus to Haemophilus influenzae type b to the occasional fungus. The shots we’ve been talking about cover exactly one of those organisms, and MenACWY covers only four of its five serogroups. “Meningitis vaccine” is a shorthand that promises a lot more than the vial delivers.

That chasm is where two kinds of false reassurance come from: the vaccine record and the rash. Neither one rules anything out.

First: “she’s vaccinated, so it can’t be meningitis.” MenACWY doesn’t cover B. No meningococcal vaccine covers pneumococcus, Hib, or any virus. And viral meningitis is the most common kind, usually self-limiting, with most people better in a week to ten days.⁵ Odds are good that what walks in to the clinic isn’t meningococcal. That’s the reassuring part, and it’s also why the shot record can’t rule anything out.

Second: the rash. In Thompson’s 2006 study of 448 children with meningococcal disease, the signs everyone watches for (rash, stiff neck, confusion) showed up at a median of 13 to 22 hours. The early ones (leg pain, cold hands and feet, off-color skin) showed up around 8 hours.⁶ What families watch for is what comes last. Know the glass test anyway, because parents ask: press a clear glass on the rash, and spots that don’t fade (petechiae and purpura) are the worrying kind. Bad thing to wait for, and harder to see on darker skin.

So instead of focusing on the symptom list when you counsel focus on the slope. A young adult who looks worse than the illness should make them look, and is worse hour to hour instead of day to day, is the one to send in.

If someone was actually exposed

Close contacts need prophylaxis fast, ideally within 24 hours. Who counts is decided by public health, not by proximity or by how worried someone is. That makes the list short to household members, roommates, and anyone directly exposed to oral secretions in the week before symptoms started. Something like a shared lecture hall or an interaction at a cash register doesn’t qualify.

Ciprofloxacin is also no longer the automatic choice. Resistant strains have been climbing since 2019, and CDC now tells health departments to prefer rifampin, ceftriaxone, or azithromycin in areas crossing two thresholds in a rolling year: two or more invasive cases caused by resistant strains, and 20% or more of cases resistant.⁷ New York went further in August 2024 and told providers to stop using cipro for this outright.⁸

Where preparation actually helps here

Most of what we do at Jase runs on a simple premise: for a short list of common, well-understood conditions, the clinical work can happen before the patient needs it, so nobody is sorting it out alone at 11pm. That’s what we mean by appropriate medical preparation.

Meningitis is where that premise stops. There’s no kit for this one. The preparation that helps a college student is a complete vaccination record and a low threshold for the ER when worrying symptoms appear.And nobody should be dosing themselves out of a standby antibiotic supply after a campus scare, a Jase kit included. That skips the resistance picture that decides the right drug, and it skips the contact tracing that decides whether they need anything at all.

We’re here for the times when primary care isn’t there, and this isn’t one of them. We’ll keep publishing where we draw these lines.

The bottom line

MenACWY is routine at 11 to 12 with a booster at 16, and it’s what the college form is asking about. MenB is a separate two-dose series under shared clinical decision-making, unless your patient is one of the people who gets it routinely. Brands don’t mix, so get the product name before dose two. And a shot record doesn’t rule meningitis out. When the slope is hours instead of days, that’s the ER.

Sources

1. CDC. Meningococcal vaccine recommendations for healthcare providers. https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html
2. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(RR-9):1-41. https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm
3. Marshall GS, Dempsey AF, Srivastava A, Isturiz RE. US College Students Are at Increased Risk for Serogroup B Meningococcal Disease. J Pediatric Infect Dis Soc. 2019;9(2):244-247. https://pmc.ncbi.nlm.nih.gov/articles/PMC7192401/
4. CDC. Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2025. MMWR. 2026;75(1). https://www.cdc.gov/mmwr/volumes/75/wr/mm7501a2.htm
5. CDC. About Viral Meningitis. https://www.cdc.gov/meningitis/about/viral-meningitis.html
6. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. https://pubmed.ncbi.nlm.nih.gov/16458763/
7. Berry I, Rubis AB, Howie RL, et al. Selection of Antibiotics as Prophylaxis for Close Contacts of Patients with Meningococcal Disease in Areas with Ciprofloxacin Resistance, United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(5):99-103. https://www.cdc.gov/mmwr/volumes/73/wr/mm7305a2.htm
8. New York State Department of Health. State directs providers to discontinue use of ciprofloxacin to prevent meningococcal disease due to increasing antimicrobial resistance. August 14, 2024. https://www.health.ny.gov/press/releases/2024/2024-08-14_ciprofloxacin.htm